nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A43—Dexamethasone—psoriasis	0.167	0.219	CbGbCtD
Ethosuximide—CYP3A5—Beclomethasone—psoriasis	0.0918	0.121	CbGbCtD
Ethosuximide—CYP3A7—Hydrocortisone—psoriasis	0.0391	0.0514	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0391	0.0514	CbGbCtD
Ethosuximide—CYP3A7—Cyclosporine—psoriasis	0.0369	0.0485	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0369	0.0485	CbGbCtD
Ethosuximide—CYP3A5—Mycophenolate mofetil—psoriasis	0.0366	0.048	CbGbCtD
Ethosuximide—CYP3A4—Calcitriol—psoriasis	0.0319	0.0419	CbGbCtD
Ethosuximide—CYP3A5—Hydrocortisone—psoriasis	0.0293	0.0385	CbGbCtD
Ethosuximide—CYP3A5—Cyclosporine—psoriasis	0.0277	0.0364	CbGbCtD
Ethosuximide—CYP3A4—Methoxsalen—psoriasis	0.0248	0.0326	CbGbCtD
Ethosuximide—CYP3A7—Dexamethasone—psoriasis	0.0243	0.0319	CbGbCtD
Ethosuximide—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0243	0.0319	CbGbCtD
Ethosuximide—CYP2E1—Dexamethasone—psoriasis	0.0235	0.0308	CbGbCtD
Ethosuximide—CYP3A5—Dexamethasone—psoriasis	0.0182	0.024	CbGbCtD
Ethosuximide—CYP3A4—Cholecalciferol—psoriasis	0.0164	0.0216	CbGbCtD
Ethosuximide—CYP3A4—Triamcinolone—psoriasis	0.0143	0.0187	CbGbCtD
Ethosuximide—CYP3A4—Mycophenolate mofetil—psoriasis	0.0143	0.0187	CbGbCtD
Ethosuximide—CYP3A4—Betamethasone—psoriasis	0.0122	0.0161	CbGbCtD
Ethosuximide—CYP3A4—Prednisolone—psoriasis	0.0121	0.0158	CbGbCtD
Ethosuximide—CYP3A4—Hydrocortisone—psoriasis	0.0114	0.015	CbGbCtD
Ethosuximide—CYP3A4—Prednisone—psoriasis	0.0114	0.015	CbGbCtD
Ethosuximide—CYP3A4—Cyclosporine—psoriasis	0.0108	0.0142	CbGbCtD
Ethosuximide—CYP3A43—Miscellaneous substrates—CYP2S1—psoriasis	0.00921	0.184	CbGpPWpGaD
Ethosuximide—CYP3A4—Dexamethasone—psoriasis	0.00711	0.00934	CbGbCtD
Ethosuximide—CYP3A43—Xenobiotics—CYP2S1—psoriasis	0.00612	0.122	CbGpPWpGaD
Ethosuximide—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00288	0.0574	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00254	0.0506	CbGpPWpGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00251	0.05	CbGpPWpGaD
Ethosuximide—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00246	0.0491	CbGpPWpGaD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00206	0.0411	CbGpPWpGaD
Ethosuximide—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00179	0.0356	CbGpPWpGaD
Ethosuximide—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00178	0.0355	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—CYP2S1—psoriasis	0.00109	0.0218	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP2S1—psoriasis	0.00108	0.0215	CbGpPWpGaD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00102	0.0204	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00101	0.0201	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00083	0.0165	CbGpPWpGaD
Ethosuximide—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000828	0.0165	CbGpPWpGaD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000741	0.0148	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00074	0.0147	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000732	0.0146	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00073	0.0146	CbGpPWpGaD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000601	0.012	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0006	0.012	CbGpPWpGaD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—TYK2—psoriasis	0.000459	0.00916	CbGpPWpGaD
Ethosuximide—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000441	0.00878	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000435	0.00866	CbGpPWpGaD
Ethosuximide—Leukopenia—Mycophenolic acid—psoriasis	0.00036	0.00191	CcSEcCtD
Ethosuximide—Connective tissue disorder—Mycophenolate mofetil—psoriasis	0.000358	0.0019	CcSEcCtD
Ethosuximide—Asthenia—Acitretin—psoriasis	0.000358	0.0019	CcSEcCtD
Ethosuximide—Urethral disorder—Mycophenolate mofetil—psoriasis	0.000357	0.0019	CcSEcCtD
Ethosuximide—Vomiting—Calcitriol—psoriasis	0.000356	0.00189	CcSEcCtD
Ethosuximide—Rash—Calcitriol—psoriasis	0.000353	0.00188	CcSEcCtD
Ethosuximide—Dermatitis—Calcitriol—psoriasis	0.000353	0.00187	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—psoriasis	0.000351	0.007	CbGpPWpGaD
Ethosuximide—Headache—Calcitriol—psoriasis	0.000351	0.00186	CcSEcCtD
Ethosuximide—Psychotic disorder—Prednisone—psoriasis	0.000348	0.00185	CcSEcCtD
Ethosuximide—Somnolence—Hydroxyurea—psoriasis	0.000348	0.00185	CcSEcCtD
Ethosuximide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000344	0.00685	CbGpPWpGaD
Ethosuximide—Diarrhoea—Acitretin—psoriasis	0.000341	0.00181	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000341	0.00679	CbGpPWpGaD
Ethosuximide—Irritability—Prednisone—psoriasis	0.000341	0.00181	CcSEcCtD
Ethosuximide—Eye disorder—Mycophenolate mofetil—psoriasis	0.00034	0.00181	CcSEcCtD
Ethosuximide—Decreased appetite—Hydroxyurea—psoriasis	0.00034	0.00181	CcSEcCtD
Ethosuximide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.00034	0.00181	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.00034	0.0018	CcSEcCtD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000339	0.00676	CbGpPWpGaD
Ethosuximide—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000338	0.00179	CcSEcCtD
Ethosuximide—Fatigue—Hydroxyurea—psoriasis	0.000337	0.00179	CcSEcCtD
Ethosuximide—Mediastinal disorder—Cyclosporine—psoriasis	0.000336	0.00179	CcSEcCtD
Ethosuximide—Nausea—Calcitriol—psoriasis	0.000333	0.00177	CcSEcCtD
Ethosuximide—Dizziness—Acitretin—psoriasis	0.00033	0.00175	CcSEcCtD
Ethosuximide—Dizziness—Fluocinolone Acetonide—psoriasis	0.000329	0.00175	CcSEcCtD
Ethosuximide—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000328	0.00174	CcSEcCtD
Ethosuximide—Mental disorder—Cyclosporine—psoriasis	0.000327	0.00174	CcSEcCtD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—psoriasis	0.000327	0.00651	CbGpPWpGaD
Ethosuximide—Connective tissue disorder—Hydrocortisone—psoriasis	0.000326	0.00173	CcSEcCtD
Ethosuximide—Malnutrition—Cyclosporine—psoriasis	0.000325	0.00173	CcSEcCtD
Ethosuximide—Nervous system disorder—Mycophenolic acid—psoriasis	0.000321	0.00171	CcSEcCtD
Ethosuximide—Weight decreased—Betamethasone—psoriasis	0.00032	0.0017	CcSEcCtD
Ethosuximide—Weight decreased—Dexamethasone—psoriasis	0.00032	0.0017	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000319	0.00636	CbGpPWpGaD
Ethosuximide—Mental disorder—Mycophenolate mofetil—psoriasis	0.000319	0.00169	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000319	0.00635	CbGpPWpGaD
Ethosuximide—Skin disorder—Mycophenolic acid—psoriasis	0.000318	0.00169	CcSEcCtD
Ethosuximide—Malnutrition—Mycophenolate mofetil—psoriasis	0.000317	0.00168	CcSEcCtD
Ethosuximide—Vomiting—Acitretin—psoriasis	0.000317	0.00168	CcSEcCtD
Ethosuximide—Vomiting—Fluocinolone Acetonide—psoriasis	0.000316	0.00168	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000315	0.00627	CbGpPWpGaD
Ethosuximide—Rash—Acitretin—psoriasis	0.000314	0.00167	CcSEcCtD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000314	0.00626	CbGpPWpGaD
Ethosuximide—Dermatitis—Acitretin—psoriasis	0.000314	0.00167	CcSEcCtD
Ethosuximide—Rash—Fluocinolone Acetonide—psoriasis	0.000313	0.00166	CcSEcCtD
Ethosuximide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000313	0.00166	CcSEcCtD
Ethosuximide—Anorexia—Mycophenolic acid—psoriasis	0.000312	0.00166	CcSEcCtD
Ethosuximide—Muscle spasms—Cyclosporine—psoriasis	0.000312	0.00166	CcSEcCtD
Ethosuximide—Headache—Acitretin—psoriasis	0.000312	0.00166	CcSEcCtD
Ethosuximide—Headache—Fluocinolone Acetonide—psoriasis	0.000311	0.00165	CcSEcCtD
Ethosuximide—Eye disorder—Hydrocortisone—psoriasis	0.00031	0.00165	CcSEcCtD
Ethosuximide—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000305	0.00162	CcSEcCtD
Ethosuximide—Lethargy—Methotrexate—psoriasis	0.000304	0.00162	CcSEcCtD
Ethosuximide—Immune system disorder—Hydrocortisone—psoriasis	0.0003	0.00159	CcSEcCtD
Ethosuximide—Agitation—Cyclosporine—psoriasis	0.000299	0.00159	CcSEcCtD
Ethosuximide—Nausea—Acitretin—psoriasis	0.000296	0.00157	CcSEcCtD
Ethosuximide—Nausea—Fluocinolone Acetonide—psoriasis	0.000295	0.00157	CcSEcCtD
Ethosuximide—Somnolence—Mycophenolic acid—psoriasis	0.000291	0.00155	CcSEcCtD
Ethosuximide—Agitation—Mycophenolate mofetil—psoriasis	0.000291	0.00155	CcSEcCtD
Ethosuximide—Leukopenia—Cyclosporine—psoriasis	0.000291	0.00154	CcSEcCtD
Ethosuximide—Mental disorder—Hydrocortisone—psoriasis	0.000291	0.00154	CcSEcCtD
Ethosuximide—Malnutrition—Hydrocortisone—psoriasis	0.000289	0.00153	CcSEcCtD
Ethosuximide—Hypersensitivity—Hydroxyurea—psoriasis	0.000288	0.00153	CcSEcCtD
Ethosuximide—Decreased appetite—Mycophenolic acid—psoriasis	0.000285	0.00151	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—psoriasis	0.000285	0.00151	CcSEcCtD
Ethosuximide—Leukopenia—Mycophenolate mofetil—psoriasis	0.000284	0.00151	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000283	0.0015	CcSEcCtD
Ethosuximide—Fatigue—Mycophenolic acid—psoriasis	0.000283	0.0015	CcSEcCtD
Ethosuximide—Asthenia—Hydroxyurea—psoriasis	0.000281	0.00149	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—psoriasis	0.00028	0.00149	CcSEcCtD
Ethosuximide—Weight decreased—Prednisone—psoriasis	0.000279	0.00148	CcSEcCtD
Ethosuximide—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000279	0.00556	CbGpPWpGaD
Ethosuximide—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000275	0.00549	CbGpPWpGaD
Ethosuximide—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000275	0.00548	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000275	0.00146	CcSEcCtD
Ethosuximide—Breast disorder—Methotrexate—psoriasis	0.000269	0.00143	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000268	0.00142	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000268	0.00142	CcSEcCtD
Ethosuximide—Diarrhoea—Hydroxyurea—psoriasis	0.000268	0.00142	CcSEcCtD
Ethosuximide—Eye disorder—Dexamethasone—psoriasis	0.000265	0.00141	CcSEcCtD
Ethosuximide—Eye disorder—Betamethasone—psoriasis	0.000265	0.00141	CcSEcCtD
Ethosuximide—Nervous system disorder—Cyclosporine—psoriasis	0.00026	0.00138	CcSEcCtD
Ethosuximide—Abdominal pain—Mycophenolic acid—psoriasis	0.000259	0.00138	CcSEcCtD
Ethosuximide—Dizziness—Hydroxyurea—psoriasis	0.000259	0.00137	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—CARM1—psoriasis	0.000258	0.00514	CbGpPWpGaD
Ethosuximide—Skin disorder—Cyclosporine—psoriasis	0.000258	0.00137	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—psoriasis	0.000255	0.00136	CcSEcCtD
Ethosuximide—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000254	0.00135	CcSEcCtD
Ethosuximide—Anorexia—Cyclosporine—psoriasis	0.000253	0.00134	CcSEcCtD
Ethosuximide—Skin disorder—Mycophenolate mofetil—psoriasis	0.000251	0.00133	CcSEcCtD
Ethosuximide—Vomiting—Hydroxyurea—psoriasis	0.000249	0.00132	CcSEcCtD
Ethosuximide—Abdominal discomfort—Methotrexate—psoriasis	0.000247	0.00131	CcSEcCtD
Ethosuximide—Rash—Hydroxyurea—psoriasis	0.000247	0.00131	CcSEcCtD
Ethosuximide—Anorexia—Mycophenolate mofetil—psoriasis	0.000247	0.00131	CcSEcCtD
Ethosuximide—Dermatitis—Hydroxyurea—psoriasis	0.000247	0.00131	CcSEcCtD
Ethosuximide—Headache—Hydroxyurea—psoriasis	0.000245	0.0013	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—psoriasis	0.000245	0.0013	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000244	0.0013	CcSEcCtD
Ethosuximide—Connective tissue disorder—Prednisone—psoriasis	0.000243	0.00129	CcSEcCtD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000237	0.00473	CbGpPWpGaD
Ethosuximide—Somnolence—Cyclosporine—psoriasis	0.000236	0.00125	CcSEcCtD
Ethosuximide—Asthenia—Mycophenolic acid—psoriasis	0.000235	0.00125	CcSEcCtD
Ethosuximide—Nausea—Hydroxyurea—psoriasis	0.000232	0.00123	CcSEcCtD
Ethosuximide—Nervous system disorder—Hydrocortisone—psoriasis	0.000231	0.00123	CcSEcCtD
Ethosuximide—Eye disorder—Prednisone—psoriasis	0.000231	0.00122	CcSEcCtD
Ethosuximide—Decreased appetite—Cyclosporine—psoriasis	0.000231	0.00122	CcSEcCtD
Ethosuximide—Somnolence—Mycophenolate mofetil—psoriasis	0.00023	0.00122	CcSEcCtD
Ethosuximide—Drowsiness—Methotrexate—psoriasis	0.00023	0.00122	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000229	0.00122	CcSEcCtD
Ethosuximide—Skin disorder—Hydrocortisone—psoriasis	0.000229	0.00122	CcSEcCtD
Ethosuximide—Fatigue—Cyclosporine—psoriasis	0.000229	0.00121	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—psoriasis	0.000228	0.00121	CcSEcCtD
Ethosuximide—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000225	0.00119	CcSEcCtD
Ethosuximide—CACNA1G—NCAM signaling for neurite out-growth—IL6—psoriasis	0.000225	0.00448	CbGpPWpGaD
Ethosuximide—Anorexia—Hydrocortisone—psoriasis	0.000225	0.00119	CcSEcCtD
Ethosuximide—Diarrhoea—Mycophenolic acid—psoriasis	0.000224	0.00119	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000223	0.00119	CcSEcCtD
Ethosuximide—Immune system disorder—Prednisone—psoriasis	0.000223	0.00118	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—NDUFA5—psoriasis	0.00022	0.00439	CbGpPWpGaD
Ethosuximide—Haematuria—Methotrexate—psoriasis	0.000219	0.00116	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Cyclosporine—psoriasis	0.000217	0.00115	CcSEcCtD
Ethosuximide—Dizziness—Mycophenolic acid—psoriasis	0.000217	0.00115	CcSEcCtD
Ethosuximide—Mental disorder—Prednisone—psoriasis	0.000216	0.00115	CcSEcCtD
Ethosuximide—Malnutrition—Prednisone—psoriasis	0.000215	0.00114	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—psoriasis	0.000214	0.00114	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000212	0.00112	CcSEcCtD
Ethosuximide—Urticaria—Cyclosporine—psoriasis	0.000211	0.00112	CcSEcCtD
Ethosuximide—Abdominal pain—Cyclosporine—psoriasis	0.00021	0.00111	CcSEcCtD
Ethosuximide—Vomiting—Mycophenolic acid—psoriasis	0.000208	0.00111	CcSEcCtD
Ethosuximide—Rash—Mycophenolic acid—psoriasis	0.000207	0.0011	CcSEcCtD
Ethosuximide—Dermatitis—Mycophenolic acid—psoriasis	0.000206	0.0011	CcSEcCtD
Ethosuximide—Urticaria—Mycophenolate mofetil—psoriasis	0.000206	0.00109	CcSEcCtD
Ethosuximide—Headache—Mycophenolic acid—psoriasis	0.000205	0.00109	CcSEcCtD
Ethosuximide—Decreased appetite—Hydrocortisone—psoriasis	0.000205	0.00109	CcSEcCtD
Ethosuximide—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000205	0.00109	CcSEcCtD
Ethosuximide—Urinary tract disorder—Methotrexate—psoriasis	0.000204	0.00108	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000203	0.00108	CcSEcCtD
Ethosuximide—Fatigue—Hydrocortisone—psoriasis	0.000203	0.00108	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—psoriasis	0.000202	0.00107	CcSEcCtD
Ethosuximide—Nervous system disorder—Betamethasone—psoriasis	0.000197	0.00105	CcSEcCtD
Ethosuximide—Nervous system disorder—Dexamethasone—psoriasis	0.000197	0.00105	CcSEcCtD
Ethosuximide—Agitation—Prednisone—psoriasis	0.000197	0.00105	CcSEcCtD
Ethosuximide—Hypersensitivity—Cyclosporine—psoriasis	0.000195	0.00104	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—psoriasis	0.000195	0.00104	CcSEcCtD
Ethosuximide—Nausea—Mycophenolic acid—psoriasis	0.000195	0.00103	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—psoriasis	0.000193	0.00102	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000193	0.00102	CcSEcCtD
Ethosuximide—Anorexia—Betamethasone—psoriasis	0.000192	0.00102	CcSEcCtD
Ethosuximide—Anorexia—Dexamethasone—psoriasis	0.000192	0.00102	CcSEcCtD
Ethosuximide—Urticaria—Prednisolone—psoriasis	0.000192	0.00102	CcSEcCtD
Ethosuximide—Fatigue—Triamcinolone—psoriasis	0.000191	0.00102	CcSEcCtD
Ethosuximide—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000191	0.00101	CcSEcCtD
Ethosuximide—Asthenia—Cyclosporine—psoriasis	0.00019	0.00101	CcSEcCtD
Ethosuximide—Urticaria—Hydrocortisone—psoriasis	0.000187	0.000994	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CYP2S1—psoriasis	0.000187	0.00373	CbGpPWpGaD
Ethosuximide—Immune system disorder—Methotrexate—psoriasis	0.000186	0.000989	CcSEcCtD
Ethosuximide—Abdominal pain—Hydrocortisone—psoriasis	0.000186	0.000989	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—psoriasis	0.000186	0.000987	CcSEcCtD
Ethosuximide—Asthenia—Mycophenolate mofetil—psoriasis	0.000186	0.000986	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000182	0.000965	CcSEcCtD
Ethosuximide—Diarrhoea—Cyclosporine—psoriasis	0.000181	0.000964	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—psoriasis	0.000181	0.00096	CcSEcCtD
Ethosuximide—Malnutrition—Methotrexate—psoriasis	0.00018	0.000954	CcSEcCtD
Ethosuximide—Hypersensitivity—Prednisolone—psoriasis	0.000178	0.000944	CcSEcCtD
Ethosuximide—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000177	0.00094	CcSEcCtD
Ethosuximide—Urticaria—Triamcinolone—psoriasis	0.000176	0.000936	CcSEcCtD
Ethosuximide—Dizziness—Cyclosporine—psoriasis	0.000175	0.000931	CcSEcCtD
Ethosuximide—Decreased appetite—Dexamethasone—psoriasis	0.000175	0.00093	CcSEcCtD
Ethosuximide—Decreased appetite—Betamethasone—psoriasis	0.000175	0.00093	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Betamethasone—psoriasis	0.000174	0.000923	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000174	0.000923	CcSEcCtD
Ethosuximide—Hypersensitivity—Hydrocortisone—psoriasis	0.000174	0.000922	CcSEcCtD
Ethosuximide—Fatigue—Betamethasone—psoriasis	0.000174	0.000922	CcSEcCtD
Ethosuximide—Fatigue—Dexamethasone—psoriasis	0.000174	0.000922	CcSEcCtD
Ethosuximide—Nervous system disorder—Prednisone—psoriasis	0.000172	0.000913	CcSEcCtD
Ethosuximide—Dizziness—Mycophenolate mofetil—psoriasis	0.000171	0.000908	CcSEcCtD
Ethosuximide—Skin disorder—Prednisone—psoriasis	0.00017	0.000905	CcSEcCtD
Ethosuximide—Asthenia—Hydrocortisone—psoriasis	0.000169	0.000898	CcSEcCtD
Ethosuximide—Vomiting—Cyclosporine—psoriasis	0.000169	0.000895	CcSEcCtD
Ethosuximide—Rash—Cyclosporine—psoriasis	0.000167	0.000888	CcSEcCtD
Ethosuximide—Anorexia—Prednisone—psoriasis	0.000167	0.000888	CcSEcCtD
Ethosuximide—Dermatitis—Cyclosporine—psoriasis	0.000167	0.000887	CcSEcCtD
Ethosuximide—Headache—Cyclosporine—psoriasis	0.000166	0.000882	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Dexamethasone—psoriasis	0.000165	0.000874	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Betamethasone—psoriasis	0.000165	0.000874	CcSEcCtD
Ethosuximide—Vomiting—Mycophenolate mofetil—psoriasis	0.000164	0.000873	CcSEcCtD
Ethosuximide—Hypersensitivity—Triamcinolone—psoriasis	0.000163	0.000868	CcSEcCtD
Ethosuximide—Rash—Mycophenolate mofetil—psoriasis	0.000163	0.000866	CcSEcCtD
Ethosuximide—Dermatitis—Mycophenolate mofetil—psoriasis	0.000163	0.000865	CcSEcCtD
Ethosuximide—Headache—Mycophenolate mofetil—psoriasis	0.000162	0.000861	CcSEcCtD
Ethosuximide—Diarrhoea—Hydrocortisone—psoriasis	0.000161	0.000856	CcSEcCtD
Ethosuximide—Leukopenia—Methotrexate—psoriasis	0.000161	0.000854	CcSEcCtD
Ethosuximide—Urticaria—Betamethasone—psoriasis	0.00016	0.000849	CcSEcCtD
Ethosuximide—Urticaria—Dexamethasone—psoriasis	0.00016	0.000849	CcSEcCtD
Ethosuximide—Dizziness—Prednisolone—psoriasis	0.00016	0.000847	CcSEcCtD
Ethosuximide—Asthenia—Triamcinolone—psoriasis	0.000159	0.000846	CcSEcCtD
Ethosuximide—Abdominal pain—Betamethasone—psoriasis	0.000159	0.000845	CcSEcCtD
Ethosuximide—Abdominal pain—Dexamethasone—psoriasis	0.000159	0.000845	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000158	0.00315	CbGpPWpGaD
Ethosuximide—Nausea—Cyclosporine—psoriasis	0.000158	0.000837	CcSEcCtD
Ethosuximide—Dizziness—Hydrocortisone—psoriasis	0.000156	0.000828	CcSEcCtD
Ethosuximide—Nausea—Mycophenolate mofetil—psoriasis	0.000154	0.000816	CcSEcCtD
Ethosuximide—Decreased appetite—Prednisone—psoriasis	0.000152	0.00081	CcSEcCtD
Ethosuximide—Rash—Prednisolone—psoriasis	0.000152	0.000808	CcSEcCtD
Ethosuximide—Dermatitis—Prednisolone—psoriasis	0.000152	0.000807	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000152	0.000806	CcSEcCtD
Ethosuximide—Fatigue—Prednisone—psoriasis	0.000151	0.000803	CcSEcCtD
Ethosuximide—Headache—Prednisolone—psoriasis	0.000151	0.000803	CcSEcCtD
Ethosuximide—Vomiting—Hydrocortisone—psoriasis	0.00015	0.000796	CcSEcCtD
Ethosuximide—Rash—Hydrocortisone—psoriasis	0.000149	0.000789	CcSEcCtD
Ethosuximide—Dermatitis—Hydrocortisone—psoriasis	0.000148	0.000788	CcSEcCtD
Ethosuximide—CYP3A4—Biological oxidations—CYP2S1—psoriasis	0.000148	0.00295	CbGpPWpGaD
Ethosuximide—Headache—Hydrocortisone—psoriasis	0.000148	0.000784	CcSEcCtD
Ethosuximide—Dizziness—Triamcinolone—psoriasis	0.000147	0.000779	CcSEcCtD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000146	0.00291	CbGpPWpGaD
Ethosuximide—Asthenia—Betamethasone—psoriasis	0.000144	0.000767	CcSEcCtD
Ethosuximide—Asthenia—Dexamethasone—psoriasis	0.000144	0.000767	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—psoriasis	0.000144	0.000763	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Prednisone—psoriasis	0.000143	0.000761	CcSEcCtD
Ethosuximide—Nausea—Prednisolone—psoriasis	0.000143	0.000761	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—psoriasis	0.000142	0.000756	CcSEcCtD
Ethosuximide—Vomiting—Triamcinolone—psoriasis	0.000141	0.000749	CcSEcCtD
Ethosuximide—Nausea—Hydrocortisone—psoriasis	0.00014	0.000743	CcSEcCtD
Ethosuximide—Rash—Triamcinolone—psoriasis	0.00014	0.000743	CcSEcCtD
Ethosuximide—Dermatitis—Triamcinolone—psoriasis	0.00014	0.000742	CcSEcCtD
Ethosuximide—Anorexia—Methotrexate—psoriasis	0.00014	0.000742	CcSEcCtD
Ethosuximide—Urticaria—Prednisone—psoriasis	0.000139	0.00074	CcSEcCtD
Ethosuximide—Headache—Triamcinolone—psoriasis	0.000139	0.000738	CcSEcCtD
Ethosuximide—Abdominal pain—Prednisone—psoriasis	0.000139	0.000736	CcSEcCtD
Ethosuximide—Diarrhoea—Betamethasone—psoriasis	0.000138	0.000732	CcSEcCtD
Ethosuximide—Diarrhoea—Dexamethasone—psoriasis	0.000138	0.000732	CcSEcCtD
Ethosuximide—Dizziness—Betamethasone—psoriasis	0.000133	0.000707	CcSEcCtD
Ethosuximide—Dizziness—Dexamethasone—psoriasis	0.000133	0.000707	CcSEcCtD
Ethosuximide—Nausea—Triamcinolone—psoriasis	0.000132	0.0007	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—TYK2—psoriasis	0.000132	0.00263	CbGpPWpGaD
Ethosuximide—Somnolence—Methotrexate—psoriasis	0.00013	0.000692	CcSEcCtD
Ethosuximide—Hypersensitivity—Prednisone—psoriasis	0.000129	0.000686	CcSEcCtD
Ethosuximide—Vomiting—Dexamethasone—psoriasis	0.000128	0.00068	CcSEcCtD
Ethosuximide—Vomiting—Betamethasone—psoriasis	0.000128	0.00068	CcSEcCtD
Ethosuximide—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000128	0.00255	CbGpPWpGaD
Ethosuximide—Decreased appetite—Methotrexate—psoriasis	0.000127	0.000677	CcSEcCtD
Ethosuximide—Rash—Dexamethasone—psoriasis	0.000127	0.000674	CcSEcCtD
Ethosuximide—Rash—Betamethasone—psoriasis	0.000127	0.000674	CcSEcCtD
Ethosuximide—Dermatitis—Dexamethasone—psoriasis	0.000127	0.000674	CcSEcCtD
Ethosuximide—Dermatitis—Betamethasone—psoriasis	0.000127	0.000674	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—psoriasis	0.000127	0.000672	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—psoriasis	0.000126	0.000671	CcSEcCtD
Ethosuximide—Headache—Dexamethasone—psoriasis	0.000126	0.00067	CcSEcCtD
Ethosuximide—Headache—Betamethasone—psoriasis	0.000126	0.00067	CcSEcCtD
Ethosuximide—Asthenia—Prednisone—psoriasis	0.000126	0.000668	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—LEP—psoriasis	0.000123	0.00246	CbGpPWpGaD
Ethosuximide—Diarrhoea—Prednisone—psoriasis	0.00012	0.000637	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—psoriasis	0.00012	0.000636	CcSEcCtD
Ethosuximide—Nausea—Dexamethasone—psoriasis	0.00012	0.000635	CcSEcCtD
Ethosuximide—Nausea—Betamethasone—psoriasis	0.00012	0.000635	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—psoriasis	0.000116	0.000618	CcSEcCtD
Ethosuximide—Dizziness—Prednisone—psoriasis	0.000116	0.000616	CcSEcCtD
Ethosuximide—Abdominal pain—Methotrexate—psoriasis	0.000116	0.000615	CcSEcCtD
Ethosuximide—Vomiting—Prednisone—psoriasis	0.000111	0.000592	CcSEcCtD
Ethosuximide—Rash—Prednisone—psoriasis	0.000111	0.000587	CcSEcCtD
Ethosuximide—Dermatitis—Prednisone—psoriasis	0.00011	0.000587	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.00011	0.0022	CbGpPWpGaD
Ethosuximide—Headache—Prednisone—psoriasis	0.00011	0.000583	CcSEcCtD
Ethosuximide—Hypersensitivity—Methotrexate—psoriasis	0.000108	0.000573	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—PPARG—psoriasis	0.000107	0.00214	CbGpPWpGaD
Ethosuximide—Asthenia—Methotrexate—psoriasis	0.000105	0.000558	CcSEcCtD
Ethosuximide—Nausea—Prednisone—psoriasis	0.000104	0.000553	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—psoriasis	0.0001	0.000532	CcSEcCtD
Ethosuximide—Dizziness—Methotrexate—psoriasis	9.69e-05	0.000515	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—TYK2—psoriasis	9.4e-05	0.00187	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—VEGFA—psoriasis	9.32e-05	0.00186	CbGpPWpGaD
Ethosuximide—Vomiting—Methotrexate—psoriasis	9.32e-05	0.000495	CcSEcCtD
Ethosuximide—Rash—Methotrexate—psoriasis	9.24e-05	0.000491	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—psoriasis	9.23e-05	0.00049	CcSEcCtD
Ethosuximide—Headache—Methotrexate—psoriasis	9.18e-05	0.000488	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CARM1—psoriasis	9.14e-05	0.00182	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NDUFA5—psoriasis	8.86e-05	0.00177	CbGpPWpGaD
Ethosuximide—Nausea—Methotrexate—psoriasis	8.7e-05	0.000462	CcSEcCtD
Ethosuximide—CYP3A7—Metabolism—CYP2S1—psoriasis	7.54e-05	0.0015	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—NFKB1—psoriasis	7.33e-05	0.00146	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—VEGFA—psoriasis	6.65e-05	0.00133	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—STAT3—psoriasis	6.58e-05	0.00131	CbGpPWpGaD
Ethosuximide—CACNA1G—Axon guidance—IL6—psoriasis	6.45e-05	0.00128	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NDUFA5—psoriasis	6.42e-05	0.00128	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NDUFA5—psoriasis	6.41e-05	0.00128	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—TNF—psoriasis	5.7e-05	0.00114	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—CAT—psoriasis	5.62e-05	0.00112	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP2S1—psoriasis	5.46e-05	0.00109	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP2S1—psoriasis	5.45e-05	0.00109	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—IL6—psoriasis	4.6e-05	0.000917	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—APOE—psoriasis	4.37e-05	0.00087	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PPARG—psoriasis	3.8e-05	0.000758	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CARM1—psoriasis	3.68e-05	0.000734	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NDUFA5—psoriasis	2.98e-05	0.000594	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CARM1—psoriasis	2.67e-05	0.000531	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CARM1—psoriasis	2.66e-05	0.00053	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CYP2S1—psoriasis	2.53e-05	0.000505	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CAT—psoriasis	2.26e-05	0.000451	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—APOE—psoriasis	1.76e-05	0.000351	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CAT—psoriasis	1.64e-05	0.000327	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CAT—psoriasis	1.64e-05	0.000326	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PPARG—psoriasis	1.53e-05	0.000305	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—APOE—psoriasis	1.27e-05	0.000254	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—APOE—psoriasis	1.27e-05	0.000253	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CARM1—psoriasis	1.24e-05	0.000247	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PPARG—psoriasis	1.11e-05	0.000221	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PPARG—psoriasis	1.11e-05	0.000221	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—CAT—psoriasis	7.61e-06	0.000152	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—APOE—psoriasis	5.91e-06	0.000118	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PPARG—psoriasis	5.15e-06	0.000103	CbGpPWpGaD
